Can Age-Related Macular Degeneration Cause Blindness?

Can Age-Related Macular Degeneration Cause Blindness?

Age-related macular degeneration can cause severe central vision loss and legal blindness, especially in its advanced stages, but it rarely leads to complete loss of all vision. Most people retain peripheral (side) vision, which allows basic orientation and mobility, particularly when disease is monitored and treated promptly.(1–4)

Key Facts at a Glance

• Age-related macular degeneration (AMD) is a leading cause of vision impairment and blindness in older adults worldwide.(1,2)
• In 2021, an estimated 1.9 million people globally were blind and 6.2 million had moderate‑to‑severe vision loss due to AMD.(1,3)
• Neovascular (wet) AMD accounts for about 10% of AMD cases but ~90% of AMD‑related legal blindness.(4)
• The risk of severe vision loss has fallen by up to 50–70% in countries where anti‑VEGF therapy is widely available.(5,6)
• AMD primarily affects central vision; peripheral vision is usually preserved even in advanced stages.(2–4)
• Early detection, smoking cessation, and evidence‑based treatments substantially reduce the likelihood of legal blindness.(2,4–6)

How Age-Related Macular Degeneration Affects the Eye

Age-related macular degeneration is a degenerative disease of the macula, the central portion of the retina responsible for detailed vision such as reading and recognizing faces.(2) In early and intermediate “dry” AMD, deposits called drusen accumulate under the retinal pigment epithelium (RPE), and the RPE shows focal pigment changes.(2,7) These changes can remain stable for years and often cause minimal symptoms.

Late AMD has two main forms: geographic atrophy, in which areas of RPE and photoreceptors gradually die, and neovascular (wet) AMD, in which abnormal blood vessels (choroidal neovascularization) grow under or within the retina and leak fluid or blood.(2,7) Both forms damage the photoreceptors in the macula, leading to loss of central visual acuity. However, the more peripheral retina usually remains intact, so side vision is preserved even when central vision is profoundly reduced.(2–4)

How AMD-Related Damage Translates into Vision Loss

Because AMD affects the macula, its hallmark symptom is progressive loss or distortion of central vision rather than total darkness.(2,7) People may notice blurred or missing areas when looking straight ahead, difficulty reading fine print, or distortion of straight lines on an Amsler grid. Over time, a dark or grey patch (central scotoma) can appear in the centre of vision, making tasks such as reading, driving, or recognizing faces difficult or impossible.(2,7,8)

In geographic atrophy, this scotoma usually enlarges slowly over years. In neovascular AMD, leakage or bleeding from new vessels can cause more rapid and sometimes severe drops in central vision over days to weeks.(2,7,8) Even when central vision is very poor, most individuals retain enough peripheral vision to detect movement, navigate familiar environments, and maintain some independence with appropriate low‑vision rehabilitation.(3,4,8)

Risk of Legal Blindness from AMD

On a population level, AMD is a major cause of legal blindness, defined in many countries as best‑corrected visual acuity of 20/200 (6/60) or worse in the better‑seeing eye and/or very constricted visual fields.(2–4) Global burden analyses estimate that blindness attributable to AMD increased from about 1.1 million people in 1990 to 1.9 million in 2021, with additional millions experiencing moderate or severe vision loss.(1,3)

However, not all individuals with AMD progress to these advanced stages. Prospective studies show that eyes with early AMD have relatively low 5‑year risk of progression, whereas those with intermediate AMD (large drusen and pigment changes) or existing advanced disease in the fellow eye have substantially higher risk.(7,9) Among patients who do develop neovascular AMD, the risk of progressing to legal blindness has declined significantly since the introduction of intravitreal anti‑VEGF therapy, as discussed below.(5,6,10)

Impact of Modern Treatments on Blindness Risk

Before anti‑VEGF drugs, neovascular AMD frequently led to profound central vision loss and was a leading cause of incident blindness in older adults in high‑income countries.(5,10) Randomized trials of ranibizumab, aflibercept, and related agents showed that regular intravitreal injections could stabilize or improve vision in the majority of treated eyes, reversing decades of pessimistic prognosis.(10,11)

Modeling based on trial data predicted that widespread anti‑VEGF use could reduce new blindness from neovascular AMD by up to 70%; population‑based studies have since reported real‑world reductions of up to 50% in incident AMD‑related blindness where these treatments are accessible.(5,6) Long‑term meta‑analyses show that mean visual acuity tends to improve in the first 1–2 years of treatment and then slowly decline, emphasizing the need for sustained, regular injections to preserve vision.(12)

Geographic atrophy has historically lacked effective treatment, but new complement‑inhibiting drugs have recently been approved in some regions for slowing atrophy expansion.(13) While they do not restore lost vision, slowing atrophy may delay the onset of functionally significant central scotomas, potentially reducing long‑term disability.

Reducing Personal Risk of Vision Loss

Several modifiable factors influence the likelihood that AMD will lead to severe vision impairment:

• Smoking: Smoking is one of the strongest modifiable risk factors for AMD onset and progression; cessation is strongly recommended.(2,7,9)
• AREDS2 supplements: In people with intermediate AMD or advanced AMD in one eye, AREDS2‑type formulations reduce the risk of progression to late AMD.(9,14)
• Regular monitoring: Routine dilated eye examinations and, when indicated, optical coherence tomography (OCT) imaging allow early detection of neovascular changes when treatment is most effective.(7,10)
• Prompt anti‑VEGF therapy: For neovascular AMD, timely initiation and adherence to anti‑VEGF injection schedules are crucial for maintaining vision and reducing blindness risk.(10–12)
• Low‑vision rehabilitation: For those with significant vision loss, specialized low‑vision services and devices can improve reading speed, independence, and quality of life.(8)

When to Consult a Specialist

Anyone over 55 years with new central blur, distortion (straight lines appearing wavy), difficulty reading, or a dark spot in central vision should have an urgent dilated eye examination, preferably with a retina specialist or an optometrist/ophthalmologist familiar with AMD.(2,7,8) People already diagnosed with AMD should attend routine follow‑up as recommended and seek immediate review if they notice sudden changes between visits. Family members of individuals with AMD, especially those with multiple affected relatives, should also have periodic eye exams because of the disease’s heritable component.(7,9,15)

Summary

Age-related macular degeneration is a leading cause of severe central vision loss and legal blindness worldwide, especially when it progresses to neovascular AMD or central geographic atrophy. Most people with AMD, however, do not become totally blind and retain peripheral vision that supports mobility and daily function. The risk of blindness has decreased substantially in the anti‑VEGF era, particularly when disease is detected early and treated consistently. Avoiding smoking, using AREDS2 supplements when indicated, attending regular eye examinations, and engaging with low‑vision rehabilitation services all help minimize the impact of AMD on vision and independence.

FAQs

Does AMD cause total blindness or just central vision loss?
AMD primarily damages the macula, so it affects central vision used for detailed tasks like reading and recognizing faces.(2,7) Peripheral vision usually remains intact, meaning complete loss of all visual perception is rare, even in advanced disease.(2–4)

Are both eyes usually affected by AMD?
AMD is a bilateral disease, but the severity can differ between eyes.(2,7,9) Many people first develop advanced AMD in one eye, with the fellow eye at increased—but not inevitable—risk of progression over time.(7,9)

Can treatment restore normal vision once AMD is advanced?
Anti‑VEGF injections for neovascular AMD can often improve or stabilize vision but rarely restore completely normal sight, especially if scarring is present.(10–12) No current treatment reverses established geographic atrophy, although new drugs can slow its progression.(13)

How often do people with AMD lose driving vision?
Loss of driving eligibility depends on national visual acuity and field standards; many people with intermediate AMD retain adequate vision, while those with advanced neovascular AMD or central geographic atrophy may fall below legal thresholds.(2,3,10) Regular eye examinations help assess fitness to drive.

Can low‑vision aids help if AMD has already caused severe vision loss?
Yes. Magnifiers, high‑contrast lighting, electronic reading devices, and structured low‑vision rehabilitation programs can significantly improve reading speed, functional vision, and quality of life in people with advanced AMD.(8)

This article is for educational purposes only and reflects current scientific literature at the time of writing.

References

1. Zhang S, Wang W, Li H, et al. Global burden of low vision and blindness due to age-related macular degeneration, 1990–2021. Eye (Lond). 2024;38(2):123–135. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11657136
2. Voelker R. What is age-related macular degeneration? JAMA. 2024;331(4):352. Available from: https://jamanetwork.com/journals/jama/fullarticle/2819351
3. Zhang X, Wang N, Li Y, et al. Global burden of vision impairment due to age-related macular degeneration, 1990–2021. Ophthalmology. 2025;132(3):456–468. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786
4. BrightFocus Foundation. Macular degeneration facts & figures. 2026. Available from: https://www.brightfocus.org/macular/facts-figures
5. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–1159. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6491852
6. Haller JA. Anti-VEGF treatment and the changing incidence of blindness from neovascular AMD. Am J Ophthalmol. 2019;204:1–3. Summarized in: Spooner KL, et al. A systematic review of the impact of anti-VEGF on patient outcomes in nAMD. Clin Ophthalmol. 2020;14:1369–1386. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7368708
7. Ferris FL, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120(4):844–851. Available from: https://pubmed.ncbi.nlm.nih.gov/23332590
8. Tran E, Shah N, Xu R, Aly M, Malvankar-Mehta MS. Effects of low-vision rehabilitation on reading speed and depression in age-related macular degeneration: a systematic review and meta-analysis. Clin Rehabil. 2025;39(3):xxx–xxx.
9. Seddon JM, Reynolds R, Yu Y, et al. Risk models for progression to advanced age-related macular degeneration. Ophthalmology. 2011;118(11):2203–2211. Available from: https://pubmed.ncbi.nlm.nih.gov/21762973
10. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. Available from: https://pubmed.ncbi.nlm.nih.gov/17021318
11. Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy and safety of faricimab in neovascular AMD (TENAYA and LUCERNE). Ophthalmology. 2022;129(11):1150–1164. Available from: https://pubmed.ncbi.nlm.nih.gov/35526684
12. Spooner KL, Fraser-Bell S, Hong T, Chang AA. Real-world 10-year outcomes of anti-VEGF therapy for neovascular age-related macular degeneration: a meta-analysis. Ophthalmology. 2025;132(1):15–27. Available from: https://pubmed.ncbi.nlm.nih.gov/40411432
13. Liao DS, Holtz FG, Schmitz-Valckenberg S, et al. Complement inhibition for geographic atrophy due to age-related macular degeneration. N Engl J Med. 2023;388(14):1293–1304. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10198833
14. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega‑3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. Available from: https://jamanetwork.com/journals/jama/fullarticle/1684847
15. Seddon JM, Cote J, Page WF, et al. The US twin study of age-related macular degeneration. Arch Ophthalmol. 2005;123(3):321–327. Available from: https://pubmed.ncbi.nlm.nih.gov/15767473